Pharmaceutical companies market research

But assume that those barriers are overcome and a pharmaceutical company markets an important drug based on pharmacogenomics. Assume, for example, that pharmacogenomics research allows the firm to know which 80% of the population will benefit from the drug, which 10% will receive absolutely no benefit, and which 10% will be seriously harmed by it. The short-term consequence would be to improve health outcomes of everyone, not just the 80% who would benefit but the other 20% who should not take the drug. The dynamic consequences are less clear. If such pharmacogenomic... 

It is interesting to remark that the total cardiovascular market has been US 65 billion in 1998 and that 48 out of the top 50 pharmaceutical companies have research projects in the CVD field. 

Data-Star. This is Europe s leading on-line database service (39) and covers worldwide business news, financial information, market research, trade statistics, business analysis, healthcare / pharmaceuticals, chemicals / petrochemicals, chemical industry, biomedicine /life science, biotechnology, and technology, with an emphasis on Europe. It was originally formed as a joint venture among BRS, Predicasts, and Radio Suisse (the Swiss telecommunications company) (37). Data-Star offers access to about 300 bibliographic, abstract, directory, and fuU-text on-line databases, of which approximately 150 are also available on Dialog (40). 

PhRMA is a trade association of over 100 research-based pharmaceutical companies. For membership a company must manufacture and market finished dosage-form products under its own brand names and must conduct a significant amount of research and development in the United States. 

In 2006 the company spent US 7.6 billion on R D and its income for that year was US 48.4 billion. Table 1.7 clearly demonstrates that pharmaceutical companies are heavily research based Pfizer s R D expenditure is head and shoulders above other technology companies with much higher market capitalization. 

Post-marketing trials of recently licensed medicines have been used as an opportunity for a pharmaceutical company to familiarise a doctor with a new product. Such studies have more to do with the marketing department of the pharmaceutical company than with serious research. Although regulatory authorities do not encourage such studies, there are undoubtedly several therapeutic issues, particularly related to safety, that remain to be answered at the... 

The only exception to this is market research material which need not reveal the name of the company involved but must state that it is sponsored by a pharmaceutical company. 

Where market research is carried out by an agency on behalf of a pharmaceutical company, the agency must reveal the name of its client to the Prescription Medicines Code of Practice Authority when the Authority requests it to do so. When commissioning market research, a company must take steps to ensure that its identity would be so made know to the Authority should a request for that information be made. 

---